Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
This extension study of subjects previously enrolled in studies CTAP101-CL-3001 or
CTAP101-CL-3002 allows long term evaluation of the safety and efficacy of CTAP101 Capsules in
reducing elevated intact parathyroid hormone (iPTH) and correcting vitamin D insufficiency in
stage 3 or 4 chronic kidney disease patients.
Phase:
Phase 3
Details
Lead Sponsor:
OPKO Health, Inc. OPKO Ireland Global Holdings Ltd.
Treatments:
1 alpha-hydroxyergocalciferol Calcifediol Calcitriol Ergocalciferols Vitamin D